支原體檢測(cè)試劑盒 (PCR 法) - FM311
產(chǎn)品名稱
TransDetect? PCR Mycoplasma Detection Kit(FM311)
高分文獻(xiàn)集錦
?Lei Z, Meng H, Liu L, et al. Mitochondrial base editor induces substantial nuclear off-target mutations[J]. Nature, 2022.(IF 69.50)
?Huang J, Lin Q, Fei H, et al. Discovery of deaminase functions by structure-based protein clustering[J]. Cell, 2023.(IF 65.00)
?Liu J L, Yan X Q, Wu H, et al. RNA codon expansion via programmable pseudouridine editing and decoding[J]. Nature, 2025.(IF 50.50)
?Xu D, Zhao H, Jin M, et al. Modulating TRADD to restore cellular homeostasis and inhibit apoptosis[J]. Nature, 2020.(IF 42.78)
?Fei H Y, LI Y J, Liu Y J, et al. Advancing protein evolution with inverse folding models integrating structural and evolutionary constraints[J]. Cell, 2025.(IF 42.50)
?Sun C, Li H C, Liu Y J, et al. Iterative recombinase technologies for efficient and precise genome engineering across kilobase to megabase scales[J]. Cell, 2025.(IF 42.50)
?Bai X, Sun P, Wang X, et al. Structure and dynamics of the EGFR/HER2 heterodimer[J]. Cell Discovery, 2023.(IF 38.07)
?Wang D, Li X, Jiao D, et al. LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia[J]. Journal of Hematology & Oncology, 2023.(IF 28.50)
?Nian Z, Dou Y, Shen Y, et al. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation[J]. Immunity.2024.(IF 25.50)
?Li Z, Wang Z, Zhong C, et al. P53 upregulation by USP7-engaging molecular glues[J]. Science Bulletin, 2024.(IF 18.80)
?Xu J, Liang Y, Li N, et al. Clathrin-associated carriers enable recycling through a kiss-and-run mechanism[J]. Nature Cell Biology, 2024. (IF 17.30)
?Fan S, Qi M, Qi Q, et al. Targeting FAPα-positive lymph node metastatic tumor cells suppresses colorectal cancer metastasis[J]. Acta Pharmaceutica Sinica B, 2024.(IF 14.80)
?Wang J, An Z, Wu Z, et al. Spatial organization of PI3K-PI (3, 4, 5) P3-AKT signaling by focal adhesions[J]. Molecular Cell, 2024.(IF 14.50)
?Zhang W, Yin C, Qi L, et al. RFWD3 reprograms nucleotide metabolism through PHGDH to induce chemoresistance in osteosarcoma[J]. Advanced Science, 2025.(IF 14.10)
?Nian Z, Zheng X, Dou Y, et al. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells[J]. Clinical Cancer Research, 2021.(IF 12.50)
?Wang L, Wang Y, He X, et al. CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells[J]. Cell Reports Medicine, 2025.(IF 10.60)
?Gu Y, Wei X, Sun Y, et al. miR-192-5p silencing by genetic aberrations is a key event in hepatocellular carcinomas with cancer stem cell features[J]. Cancer research, 2019.(IF 8.38)
?Liu Z, Chen Z, Wang J, et al. Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance[J]. Journal of Hematology & Oncology, 2018.(IF 7.33)
?Lu B, Dong L, Yi D, et al. Transposase-assisted tagmentation of RNA/DNA hybrid duplexes[J]. Elife, 2020.(IF 7.08)
產(chǎn)品特點(diǎn)
? 靈敏度高：優(yōu)化的高敏檢測(cè)體系，最大程度的降低漏檢風(fēng)險(xiǎn)。
? 覆蓋全面：針對(duì)支原體 16S rRNA 序列設(shè)計(jì)多條特異性引物，可全面覆蓋包括實(shí)驗(yàn)室常見(jiàn)支原體污染類型在內(nèi)的 54 種支原體。
? 簡(jiǎn)便快捷：無(wú)需復(fù)雜前處理，65 min 完成擴(kuò)增，較 V1 版本擴(kuò)增時(shí)間縮短 30 min。
? 穩(wěn)定性好：耐受 5 μl 不同類型的大體積樣本，熱加速穩(wěn)定性好。
? 特異性高：與常見(jiàn)細(xì)菌及工程細(xì)胞無(wú)交叉擴(kuò)增，結(jié)果可靠。
數(shù)據(jù)展示
覆蓋度好
分別使用 TransGen 和 Company G 產(chǎn)品對(duì) 7 種常見(jiàn)支原體標(biāo)準(zhǔn)品進(jìn)行檢測(cè)，結(jié)果表明， TransGen 產(chǎn)品均能檢出，而 Company G 擴(kuò)增能力較弱。
靈敏度高
分別使用 TransGen 和 Company G 產(chǎn)品檢測(cè) 100 copies/μl 的支原體標(biāo)準(zhǔn)品，結(jié)果表明，TransGen 產(chǎn)品的檢測(cè)靈敏度可達(dá) 100 copies/μl，而 Company G 未成功檢出。
抗抑制性強(qiáng)
分別使用 TransGen 和 Company G 產(chǎn)品擴(kuò)增 1-5 μl 的支原體陽(yáng)性細(xì)胞培養(yǎng)液，結(jié)果表明，TransGen 產(chǎn)品抗抑制性好，5 μl 上樣體積仍能有效擴(kuò)增。
可檢測(cè) 54 種支原體
產(chǎn)品信息
